源自单个B细胞的新型隐球菌保护性和非保护性单克隆抗体。
Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell.
作者信息
Mukherjee J, Nussbaum G, Scharff M D, Casadevall A
机构信息
Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York 10461.
出版信息
J Exp Med. 1995 Jan 1;181(1):405-9. doi: 10.1084/jem.181.1.405.
Abstract
Two immunoglobulin M monoclonal antibodies (mAbs) derived from the same B cell recognize different epitopes on the capsular polysaccharide of the pathogenic yeast, Cryptococcus neoformans. Their respective epitopes are located in spatially distinct regions of the capsule. Passive administration of one mAb prolonged survival whereas the other mAb did not. The results indicate that specificity is an important determinant of antibody efficacy against C. neoformans and that somatic mutations occurring during the antibody response can affect the protective efficacy of antibodies to C. neoformans.
摘要
源自同一B细胞的两种免疫球蛋白M单克隆抗体（mAb）识别致病性酵母新型隐球菌荚膜多糖上的不同表位。它们各自的表位位于荚膜的空间不同区域。被动给予一种mAb可延长生存期，而另一种mAb则不能。结果表明，特异性是抗体抗新型隐球菌效力的重要决定因素，并且抗体应答过程中发生的体细胞突变可影响抗体对新型隐球菌的保护效力。
相似文献
1
Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell.
J Exp Med. 1995 Jan 1;181(1):405-9. doi: 10.1084/jem.181.1.405.
2
Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
Infect Immun. 2004 Aug;72(8):4810-8. doi: 10.1128/IAI.72.8.4810-4818.2004.
3
Protective murine monoclonal antibodies to Cryptococcus neoformans.
Infect Immun. 1992 Nov;60(11):4534-41. doi: 10.1128/iai.60.11.4534-4541.1992.
4
Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans.
J Exp Med. 1996 Apr 1;183(4):1905-9. doi: 10.1084/jem.183.4.1905.
5
6
Cryptococcus neoformans infection can elicit protective antibodies in mice.
Can J Microbiol. 1994 Oct;40(10):888-92. doi: 10.1139/m94-141.
7
Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies.
Infect Immun. 2001 May;69(5):3398-409. doi: 10.1128/IAI.69.5.3398-3409.2001.
8
Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi?
Zentralbl Bakteriol. 1996 Aug;284(4):475-95. doi: 10.1016/s0934-8840(96)80001-6.
9
Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments.
J Immunol. 2001 Feb 1;166(3):2100-7. doi: 10.4049/jimmunol.166.3.2100.
10
Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.
Antimicrob Agents Chemother. 1994 Jul;38(7):1507-14. doi: 10.1128/AAC.38.7.1507.
引用本文的文献
1
The buoyancy of cryptococcal cells and its implications for transport and persistence of in aqueous environments.
mSphere. 2024 Dec 19;9(12):e0084824. doi: 10.1128/msphere.00848-24. Epub 2024 Nov 27.
2
Monoclonal antibodies: From magic bullet to precision weapon.
Mol Biomed. 2024 Oct 11;5(1):47. doi: 10.1186/s43556-024-00210-1.
3
Antigen specificity shapes antibody functions in tuberculosis.
bioRxiv. 2024 Jul 2:2024.06.03.597169. doi: 10.1101/2024.06.03.597169.
4
The structure of a polysaccharide motif recognized by protective antibodies: A combined NMR and MD study.
Proc Natl Acad Sci U S A. 2024 Feb 13;121(7):e2315733121. doi: 10.1073/pnas.2315733121. Epub 2024 Feb 8.
5
Synthetic Glycans Reveal Determinants of Antibody Functional Efficacy against a Fungal Pathogen.
ACS Infect Dis. 2024 Feb 9;10(2):475-488. doi: 10.1021/acsinfecdis.3c00447. Epub 2023 Oct 19.
6
The structure of a polysaccharide motif recognized by protective antibodies: A combined NMR and MD study.
bioRxiv. 2023 Sep 6:2023.09.06.556507. doi: 10.1101/2023.09.06.556507.
7
Isolation and Characterization of Human Monoclonal Antibodies to Pneumococcal Capsular Polysaccharide 3.
Microbiol Spectr. 2021 Dec 22;9(3):e0144621. doi: 10.1128/Spectrum.01446-21. Epub 2021 Nov 10.
8
A synthetic glycan array containing glucuronoxylomannan capsular polysaccharide fragments allows the mapping of protective epitopes.
Chem Sci. 2020 Aug 7;11(34):9209-9217. doi: 10.1039/d0sc01249a.
9
Structural basis of Blastomyces Endoglucanase-2 adjuvancy in anti-fungal and -viral immunity.
PLoS Pathog. 2021 Mar 18;17(3):e1009324. doi: 10.1371/journal.ppat.1009324. eCollection 2021 Mar.
10
Monoclonal Antibodies as Tools to Combat Fungal Infections.
J Fungi (Basel). 2020 Feb 4;6(1):22. doi: 10.3390/jof6010022.
本文引用的文献
1
[Inhibition of leukocyte migration in vitro by a capsular polyoside of Torulopsis (Cryptococcus) neoformans].
Ann Inst Pasteur (Paris). 1951 Dec;81(6):674-6.
2
Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.
J Exp Med. 1993 Apr 1;177(4):1105-16. doi: 10.1084/jem.177.4.1105.
3
Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole.
Antimicrob Agents Chemother. 1993 Jun;37(6):1383-6. doi: 10.1128/AAC.37.6.1383.
4
Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.
Antimicrob Agents Chemother. 1994 Mar;38(3):580-7. doi: 10.1128/AAC.38.3.580.
5
Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.
Infect Immun. 1994 Mar;62(3):1079-88. doi: 10.1128/iai.62.3.1079-1088.1994.
6
Persistence of initial infection in recurrent Cryptococcus neoformans meningitis.
Lancet. 1993 Mar 6;341(8845):595-6. doi: 10.1016/0140-6736(93)90354-j.
7
Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.
Antimicrob Agents Chemother. 1994 Jul;38(7):1507-14. doi: 10.1128/AAC.38.7.1507.
8
Passive immunization in murine cryptococcosis.
Sabouraudia. 1981 Dec;19(4):237-44. doi: 10.1080/00362178185380411.
9
Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.
Infect Immun. 1981 Mar;31(3):978-84. doi: 10.1128/iai.31.3.978-984.1981.
10
Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A.
Mol Immunol. 1980 Aug;17(8):1025-32. doi: 10.1016/0161-5890(80)90096-6.
Zotero 插件